Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Abstract

To evaluate efficacy in patients with brain metastasis (BM) on entry into the lapatinib expanded access program (LEAP). LEAP is a worldwide, single-arm, open-label study. HER2-positive, locally-advanced or metastatic breast cancer patients with progression after an anthracycline, taxane, and trastuzumab were eligible. Patients received capecitabine 2000 mg… (More)
DOI: 10.1186/1471-2407-12-322

Topics

8 Figures and Tables

Slides referencing similar topics